AR and prostate cancer: These two target proteins are well‐established molecular chaperone and co‐chaperone proteins, respectively (De Leon et al., 2011; Rocchi et al., 2004; Storer Samaniego et al., 2015; Zoubeidi et al., 2007), and are known to be involved in modulating AR signaling during prostate cancer progression and development.